E
AMRX icon

Ergoteles’s Amneal Pharmaceuticals AMRX Stock Holding History

Ergoteles’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,759
Closed -$36K – 1422
2022
Q3 		$36K Buy
+17,759
New +$49.8K ﹤0.01% 1461
2021
Q3 		– Sell
-19,300
Closed -$99K – 1174
2021
Q2 		$99K Buy
+19,300
New +$110K ﹤0.01% 1414
2020
Q4 		– Sell
-10,552
Closed -$41K – 656
2020
Q3 		$41K Buy
+10,552
New +$45.1K 0.01% 562

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ergoteles's AMRX Position: Q4 2022 in Review

Ergoteles sold out of Amneal Pharmaceuticals (AMRX) in Q4 2022, closing a stake of 17,759 shares — an estimated $36K sold.

Ergoteles first reported a position in AMRX in Q3 2020 and held it in 3 quarters. The position peaked at $99K in Q2 2021. 156 funds tracked by Wall St. Rank hold AMRX as of Q4 2022.

  • Ergoteles reported no remaining Amneal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 17,759 Amneal Pharmaceuticals shares in Q4 2022, an estimated $36K.
  • Ergoteles first reported a position in Amneal Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Ergoteles's Amneal Pharmaceuticals position peaked at $99K in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.